17,261 trials
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline at Week 12 — 0.25; -0.15; -0.48; -0.42 Percent — p=<0.0001
Diabetes Mellitus, Type 2
Primary: Weighted Mean Glucose (WMG) Change From Baseline at Day 28 — 0.1; -19.8; -26.1 mg/dL — p=<0.0001
Carcinoma, Renal Cell
Primary: Number of Subjects With Overall Confirmed Objective Response (OR) — 41 participants
Gastroesophageal Reflux Disease
Primary: Total Number of Reflux Episodes During 24 Hours — 59.4; 50.7; 44.3; 38.0 Episodes
Osteomyelitis
Primary: Any Creatine Phosphokinase (CPK) Elevation > 500 Units Per Liter (U/L) — 4; 5; 2 Participants
Diabetic Macular Edema
Primary: Change in Central Subfield Thickening From Baseline Through 34 Weeks — -10; -47; -27; -16 microns — p=0.46
Previously Untreated Metastatic Colorectal Cancer
Primary: Progression-free Survival (PFS) — 6.6; 8.2 months — p=0.0048
Left Ventricle Function
Primary: Left Ventricular Ejection Fraction (LVEF), Change From Baseline — 2.00; -3.25 Percent change
Healthy
Primary: Armodafinil DAT Occupancy in Caudate — 34.0; 60.5; 40.4; 65.2 μg/mL
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 12.3; 8.5 Weeks — p=0.3206
Reflux Episodes
Primary: Number of Transient Lower Esophageal Sphincter Relaxations (TLESRs) 0-3 Hours Post Meal, Post Third Dose — 11.6; 15.5 Relaxations
Facial Wrinkles
Primary: Change in Wrinkle Severity Rating Scale — -0.94; -1.07 units on scale
Healthy
Primary: Testosterone Blood Serum Concentration — 14.25; 8.53; 9.83; 9.83 ng/dl
Healthy
Primary: Prostate Tissue DHT and Testosterone Levels After 28 Days of Treatment With Dihydrotestosterone [DHT] Gel Versus Placebo Gel. — 2.8; 3.1; 0.6; 0.4 ng/g
Acute T-Cell Leukemia-Lymphoma
Primary: Overall Response Rate — 52 percentage of participants